Clinical Trial

A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.
Trial Details
NCT Number NCT07239973
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions Healthy, Non-diabetic Overweight or Obese
Enrollment 75 participants
Start Date 2025-10-21
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-20